Bausch Health Companies Inc. (BHC)
- Previous Close
6.19 - Open
6.21 - Bid 6.13 x 2200
- Ask 6.24 x 3200
- Day's Range
6.12 - 6.33 - 52 Week Range
3.96 - 11.46 - Volume
1,425,006 - Avg. Volume
3,699,745 - Market Cap (intraday)
2.289B - Beta (5Y Monthly) 0.75
- PE Ratio (TTM)
-- - EPS (TTM)
-1.29 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Nov 10, 2010
- 1y Target Est
7.64
Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.
www.bauschhealth.com20,270
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: BHC
View MorePerformance Overview: BHC
Trailing total returns as of 9/6/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BHC
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BHC
View MoreValuation Measures
Market Cap
2.29B
Enterprise Value
23.35B
Trailing P/E
--
Forward P/E
1.51
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.25
Price/Book (mrq)
--
Enterprise Value/Revenue
2.54
Enterprise Value/EBITDA
10.06
Financial Highlights
Profitability and Income Statement
Profit Margin
-5.12%
Return on Assets (ttm)
4.16%
Return on Equity (ttm)
-2,304.54%
Revenue (ttm)
9.2B
Net Income Avi to Common (ttm)
-471M
Diluted EPS (ttm)
-1.29
Balance Sheet and Cash Flow
Total Cash (mrq)
595M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
975.5M